As one of the most frequent cancers in fair-skinned populations, melanoma mostly affects young and middle-aged people, resulting in an important socioeconomic problem.254 Moreover, males are ~1.5 times more likely to develop melanoma than females.255 Systemic therapies for melanoma have been dramatically revolutionized by the development of targeted therapies, such as BRAF and MEK inhibitors, and immunotherapies, such as anti-PD-1 antibodies. Here, BRAF is linked to melanoma.